Amylyx Pharmaceuticals Inc
Research Amylyx Pharmaceuticals Inc (AMLX) on Bullrun: market cap USD 4.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMLX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 4.17B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 43.42M
- Free cash flow-USD 31.45M
Valuation Snapshot
latest market cap is USD 4.17B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 144.74M | -USD 123.48M | n/a | -1.53 | USD 226.65M | USD 5.96M | USD 305.26M |
| FY2024 | USD 87.37M | -USD 301.74M | -USD 167.80M | 93.2% | -4.43 | USD 77.39M | USD 1.98M | USD 164.77M |
| FY2023 | USD 380.79M | USD 49.27M | USD 10.68M | 93.3% | 0.7 | USD 170.20M | USD 4.24M | USD 433.43M |
| FY2022 | USD 22.23M | -USD 198.38M | -USD 182.40M | 86.5% | -3.39 | USD 62.53M | USD 7.07M | USD 340.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.17B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.33B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 259.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 993.86M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.45B | n/a | n/a | n/a |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Amylyx Pharmaceuticals Inc's market cap?
Amylyx Pharmaceuticals Inc's market capitalization is USD 4.17B.
What does Amylyx Pharmaceuticals Inc do?
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.